J
Jyrki Taskinen
Researcher at Orion Corporation
Publications - 19
Citations - 1617
Jyrki Taskinen is an academic researcher from Orion Corporation. The author has contributed to research in topics: Mass spectrometry & Troponin C. The author has an hindex of 11, co-authored 19 publications receiving 1569 citations.
Papers
More filters
Journal ArticleDOI
Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
Timo Lotta,Jukka Vidgren,Carola Tilgmann,I. Ulmanen,Krister Melén,Ilkka Julkunen,Jyrki Taskinen +6 more
TL;DR: Comparison of velocity parameters, substrate selectivity, and regioselectivity of the methylation of both enzyme forms, and a revised mechanism for the reaction cycle are discussed.
Journal ArticleDOI
Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C : A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study
Piero Pollesello,Martti Ovaska,Juha Kaivola,Carola Tilgmann,Kenneth Lundstrom,Nisse Kalkkinen,Ismo Ulmanen,Erkki Nissinen,Jyrki Taskinen +8 more
TL;DR: The binding of a new calcium sensitizer, levosimendan, to human cardiac troponin C (cTnC) is described, and the role of Asp-88 in the binding of the drug to the NH2-terminal domain of cTNC is revealed.
Journal ArticleDOI
A model for human cardiac troponin C and for modulation of its Ca2+ affinity by drugs.
Martti Ovaska,Jyrki Taskinen +1 more
TL;DR: High resolution crystal structures of two calcium binding proteins, calmodulin and skeletal troponin C, make it possible to model in detail the calcium‐sensitizing action of drugs on tropon in C.
Journal ArticleDOI
PLS modelling of structure-activity relationships of catechol O-methyltransferase inhibitors.
TL;DR: The models reveal that inhibition activity is nonlinearly related to the size of the R5 substituent and its lipophilicity is important in the binding of inhibitors, while ionized R1 substituents decrease inhibition activity.